GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.
The user experienced significant hair regrowth using finasteride, minoxidil, and a 4,000-graft hair transplant performed by Dr. Nader in Reynosa, Mexico. The results were natural-looking, and the user plans a second transplant for additional density if needed.
Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.
The user is considering adding a topical treatment to their current regimen of finasteride and oral minoxidil to protect their temple area, with options like piro, RU58841, or topical finasteride or dutasteride. They are advised against overcomplicating their treatment, but another user suggests a topical with 8% minoxidil/dutasteride for better results.
The user experienced side effects like watery semen, erection problems, and decreased libido from finasteride, which resolved after stopping it. They are considering dutasteride mesotherapy as an alternative, as advised by their dermatologist, and are concerned about potential side effects.
A 26-year-old male experienced significant hair regrowth using finasteride and minoxidil, with no side effects, and is considering switching to dutasteride. He applies minoxidil topically and takes finasteride daily, noting the importance of consistent lighting for progress photos.
Balding scalps have more androgen receptors, leading to increased TGF-beta, which causes blood vessel loss and hair follicle miniaturization. Blocking androgen signaling and TGF-beta may help prevent hair loss.
Consider increasing dutasteride dosage to 2.5mg daily and continue using oral minoxidil. Check DHT levels, thyroid, vitamin D, and consider additional treatments like microneedling, RU58841, and improving diet and lifestyle.
A 22-year-old shared their 6-month hair loss progress using only topical treatments like minoxidil, derma rolling, and red light therapy, without finasteride or oral medications. Other users suggested adding DHT blockers like RU58841 and ketoconazole shampoo for better results.
Finasteride and Dutasteride used in combination with RU58841 and microneedling, as a treatment for hair loss. There was discussion on progress of the treatment and potential other methods to consider.
The user is hesitant to start Fin and Min due to their long-term commitment and is currently on a 2-month supplement course. Another user suggests that the supplements are ineffective and recommends using Fin and Min for androgenetic alopecia.
The user is using 5% topical minoxidil, 1mg oral finasteride, biotin, vitamin D, zinc, and microneedling for hair loss. They report no sexual side effects and feel their libido may have increased.
The user is experiencing reduced hair shedding and increased hair density after using finasteride, minoxidil, derma rolling, granactive retinoid, and Nizoral, while also taking testosterone and aromatase inhibitors. They question if they are a hyper responder to the treatments, despite mixed feedback from others about visible progress.
Minoxidil may inhibit androgen receptors and affect hormonal pathways, potentially explaining its effectiveness in treating androgenetic alopecia (AGA). Users discuss its varying effectiveness on scalp versus facial hair and note fewer side effects with topical use compared to oral.
Androgenetic alopecia is caused by DHT affecting hair growth. Finasteride and minoxidil are used to manage hair loss by blocking DHT and promoting hair growth.
RU58841 and Pyrilutamide (Kx-826) are both topical anti-androgens, but neither is effective for hair regrowth. RU58841 has more anecdotal support, while Pyrilutamide has progressed further in trials, though both have limitations.
The user noticed improvement in skin tags after using oral and topical finasteride and minoxidil, along with other supplements like thiamine, P5P, serrapeptase, nattokinase, and retinol. They are unsure which treatment caused the improvement and are seeking input on whether finasteride's DHT reduction could be responsible.
A young man with hypertrichosis has over 95% of his face covered in hair, sparking humorous comments about hair loss treatments like minoxidil and dutasteride. Users joke about transplanting his facial hair and discuss the challenges of his condition compared to typical balding.
Chinese company gets green light for Pyrilutamide Phase II trial for androgenetic alopecia. Androgen receptors downregulate in androgen deficient environments.
The user tried a home-brew topical finasteride regimen for 120 days with initial benefits but no long-term improvement, leading to continued hair shedding. They switched to oral finasteride, experiencing mild testicle discomfort but no changes in libido or erections, and plan to continue this regimen for 120 days.
A 29-year-old male experiencing hair loss due to TRT is using minoxidil and dermarolling but is hesitant to use finasteride or dutasteride due to potential side effects. He is considering low level laser therapy (LLLT), PRP, ketoconazole shampoo, and oral minoxidil as additional treatments. A reply suggests that without a DHT blocker like finasteride or dutasteride, other treatments may not be effective long-term.
A 52-year-old male with Multiple Sclerosis is considering using Finasteride and Testosterone Replacement Therapy (TRT) for hair loss but is advised to lose weight first to avoid side effects. He is currently focusing on diet, weight loss, and using Rogaine and microneedling for hair treatment.
The user experienced significant hair regrowth using a regimen of 1 mg finasteride daily, minoxidil twice daily, ketoconazole shampoo weekly, dermastamping weekly, and tretinoin. They reported no side effects and emphasized the importance of committing to the treatment.
A user experienced increased hair density loss after 4 months on dutasteride combined with finasteride. They are also using topical dutasteride with azelaic acid and alfatradiol but cannot tolerate antiandrogens like RU58841 due to headaches.
A woman with AGA and CTE has been taking multiple hair loss treatments including spironolactone, dutasteride, finasteride, bicalutamide, birth control, and minoxidil without success. Steroid injections, however, dramatically and immediately stopped her hair loss, though the effect lasts less than a month.
The conversation discusses seeking a stronger treatment than Dutasteride (DUT) for hair loss. Suggestions include combining DUT with RU58841, increasing DUT dosage, and using transgender hormone replacement therapy or testosterone blockers, though some options may have feminizing side effects.
The conversation discusses potential causes of pigmentation around hair follicles, suggesting sebum buildup, autoimmune conditions, or dermatitis. Treatments mentioned include finasteride, dutasteride, and an anti-inflammatory diet, with a recommendation to consult a doctor for a proper diagnosis.
The post and conversation discuss the link between DHT (a hormone), scalp itchiness, and hair loss. Some users share their experiences and treatments, including the use of fluconazole, corticosteroids, and ketoconazole shampoo, with one user suspecting minoxidil as a potential cause of their symptoms.
The conversation is about a user's impressive hair recovery over 14 months using 0.5mg dutasteride, 5% topical minoxidil, saw palmetto shampoo, and occasional microneedling. The results are highly praised by others, with many expressing admiration and hope for similar outcomes.
Various hair growth treatments were discussed, including microneedling, bimatoprost, setipiprant, stemoxydine, PGE2, CB-03-01, WNT Beta-Catenin upregulators, KY19382, topical estrogen, IGF-1, GH, MK-677, oral castor oil, fisetin, resveratrol, cetrizine, and lactic acid. Users shared experiences and sources for these treatments, with some expressing interest in topical solutions and others noting the lack of FDA approval or scientific evidence for certain options.